الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 92 |  |  |
| | | from | 92 | | |
Abstract
Psoriasis is considered one of the commonest chronic inflammatory immune mediated diseases caused by multiple factors. It affects the skin; however it is increasingly determined as a systemic inflammatory disorder. It affects ~ 2-3% of the population all over the world.
Psoriatic arthritis is one of the common complications of psoriasis affecting 30% of patients with psoriasis; it is considered a musculoskeletal inflammatory disorder that affects axial & peripheral joints with extra-articular manifestations.
Early diagnosis and detection of PsA and its treatment help improvement of quality of life and reduces complications. Determination of serum biomarker for PsA might help early diagnose.
MMP3 is a Zn+2 dependent endopeptidase that is known as Stromelysin-1 as well. It has a significant role in degradation of ECM, tissue remodling as well as diseases processes.
The aim of this study was to compare the serum level of MMP3 in psoriatic patients with and without PsA and to detect its correlation with disease severity.
This study found that there was a statistically significant elevated serum level of MMP3 in PsA group in comparison with both psoriatic and control groups.
This study found that there was a +ve correlation between MMP3 serum level and BMI and found that there was no relation between MMP3 level and nail dystrophy, existence of dactylitis, number of joints affected and psoriasis duration.
This study found that there was no relation between MMP3 serum level and type of treatment.
This study found that there was no relation between MMP3 serum level and psoriasis severity and found that there was no relation between psoriasis severity and existence of nail dystrophy and type of joint affected.
This study concluded that MMP3 may have a role in progression and pathogenesis of PsA in psoriatic patients.